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Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a
highly aggressive tumor that is generally fatal when it spreads beyond
the ovary. Although stage IA disease is associated with a better progno-
sis, approximately 67% of patients recur regardless of treatment type
(Young et al., 1994). Once recurrent disease develops, the tumors tend
to be poorly responsive to chemotherapy and effective treatments
have not been described (Young et al., 1994; Pautier et al., 2007;
Scully, 1993). However, there are a few reports of rare patients who
have survived after multi-modality treatment that included surgery,
chemotherapy and radiation therapy for recurrent disease (Young
et al., 1994; Cannon et al., 1975; Dickersin et al., 1982; Benrubi et al.,
1993; Harrison et al., 2006; Niimi et al., 2006; Isonishi et al., 2008;
Christin et al., 2008). Furthermore, previous reports have suggested
that radiotherapy in the adjuvant setting has activity in the primary as
well as recurrent SCCOHT (Young et al., 1994; Pautier et al., 2007;
Scully, 1993; Cannon et al., 1975; Dickersin et al., 1982). In this report,gic Oncology, Unit 1362, The
Holcombe Blvd., Houston, TX
meler).
. This is an open access article underwe describe the case of a 35-year-old woman with stage IA SCCOHT
with a sustained complete response following surgery and radiotherapy
for recurrent disease. In addition, we review the available literature de-
scribing treatment for recurrent SCCOHT.
Case report
The patient initially presented at age 35 years with pelvic pain and
abdominal distention. A contrast-enhanced computed tomography
(CT) scan revealed a large right ovarian mass extending to the level of
the umbilicus. Her CA125 level was 35 U/mL. She did not desire fertility
preservation and underwent surgery including a total abdominal
hysterectomy with bilateral salpingo-oophorectomy and a partial
omentectomy. Final pathology revealed SCCOHT of the right ovary.
The left ovary, bilateral fallopian tubes, uterus and omentum were all
negative for disease. She received four cycles of adjuvant chemotherapy
with cisplatin (75 mg/m2 on day 1) and etoposide (100 mg/m2 on days
1, 2 and 3) administered every three weeks. She tolerated the chemo-
therapy without major toxicities. After completion of chemotherapy,
imaging showed no evidence of disease. She was followed on a three-
month interval with pelvic exam, CT scan of the abdomen and pelvis,
chest radiograph, and CA125 level. Twenty months after completing
primary treatment, she developed recurrent disease with an isolatedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cluding complete resection of themass, aswell as sampling of surround-
ing left para-aortic lymph nodes and a biopsy of the remaining
omentum. Pathology conﬁrmed recurrent SCCOHT in the para-aortic
mass. The remaining para-aortic lymph nodes and omentum were
negative.
The patient received postoperative radiotherapy to the para-aortic
lymph nodes from T12/L1 to L4/L5, with an initial dose of 45 Gy using a
4-ﬁeld technique with 18 MV photons. The ﬁelds were then reduced to
cover only the operative bed as demarcated by clips placed at the time
of surgery. This region was treated for an additional 5.4 Gy to a total
dose of 50.4 Gy in 28 fractions. Treatment was delivered over a total of
36 days. No chemotherapy was given. The treatment was tolerated well
with the only symptom being mild nausea controlled with antiemetics.
Imaging at the completion of therapy showed no evidence of disease.Table 1
Long-term survivors following treatment for recurrent small cell carcinoma of the ovary, hype
Study author,
year
FIGO
stage
Age at
diagnosis
(years)
Primary
surgery
Primary adjuvant
treatment
Cannon et al.
(1975),
Young et al.
(1994)
IA 23 RSO None
Dickersin et al.
(1982)
IA 26 RSO Radiotherapy
Young et al. (1994) IA 19 RSO Chemotherapy: cisplatin,
velban, bleomycin
Young et al. (1994) IA 10 LSO Chemotherapy: cisplatin,
velban
(Young et al.
(1994), Benrubi
et al. (1993))
IIB 16 RSO Chemotherapy: cyclophospham
doxorubicin, cisplatin, vincrist
etoposide
Surgery: TH, LSO, omentectom
appendectomy, para-aortic
and pelvic LN dissection
Harrison et al.
(2006)
IC 28 USO,
omentectomy
Chemotherapy: cisplatin,
etoposide and carboplatin,
paclitaxel
Niimi et al. (2006),
Isonishi et al.
(2008)
IIC 24 LSO,
omentectomy
Chemotherapy: cisplatin,
etoposide, docetaxel
Christin et al.
(2008)
IIIC 12 LSO and
para-aortic LN
dissection
Chemotherapy: doxorubicin,
etoposide, cisplatin,
cyclophosphamide, carboplatin
Surgery: RSO, omentectomy,
pelvic and para-aortic
LN dissection
Christin et al.
(2008)
IIC 13 LSO and
omentectomy
Chemotherapy: bleomycin,
etoposide, cisplatin, ifosfamide
Surgery: TAH, RSO, omentecto
pelvic and para-aortic
LN dissection
Callegaro-Filho
(2014)
IA 35 TH, BSO, and
omentectomy
Chemotherapy: cisplatin, etopo
TH: total hysterectomy; BSO: bilateral salpingo-oophorectomy; LSO: left salpingo-oophorectomThe patient has been followed with regular CT scans, chest radiographs
and CA125 levels, and remains without evidence of disease ﬁfteen years
following the completion of radiotherapy for recurrent disease.
Discussion
SCCOHT is an aggressive disease andmost patients develop progres-
sive or recurrent disease despite treatment. No standard approach has
been recommended for the treatment of recurrent disease, although
multi-modality treatments including surgery, chemotherapy and
radiotherapy have been described. Although adjuvant thoracic
radiotherapy has been demonstrated to improve survival in conjunction
with chemotherapy in limited stage, small-cell lung carcinoma (Van
Meerbeeck et al., 2011), the role of radiotherapy in the treatment of pri-
mary or recurrent SCCOHT is unclear.rcalcemic type (SCCOHT).
Recurrence
interval
(months)
Recurrence
site
Treatment for
recurrence
Outcome
12 Pelvis Surgery: resection of the right
broad ligament.
Radiotherapy: pelvis
Chemotherapy: chlorambucil
NED at 10
years
2 Para-aortic
LN and
omentum
Surgery: TH, LSO and
retroperitoneal
LN dissection
NED at 9
months
4
18
Pelvis
Anterior
abdominal
wall
Surgery: TH and LSO
Chemotherapy: doxorubicin,
cyclophosphamide, etoposide
Radiotherapy: pelvis
Surgery: resection of mass
Chemotherapy: doxorubicin,
cyclophosphamide, etoposide
NED at 45
months
5 Para-aortic
LN
Chemotherapy: cisplatin,
velban,
doxorubicin, vinblastine,
etoposide
NED at 4
years, 5
months
ide,
ine,
y,
6 NR Surgery: TH, LSO, omentectomy,
para-aortic LN dissection.
Radiotherapy: whole abdomen
NED at 7
years
9 NR Surgery: USO and omentectomy. NED at 16
months
8 Uterus Surgery: TH and pelvic
lymphadenectomy.
Chemotherapy: docetaxel
NED at 4
years
2 Pelvis Surgery: resection of parietal
nodule
and TH. Chemotherapy:
carboplatin
and ifosfamide followed by
high-dose
chemotherapy (carboplatin,
etoposide, melphalan)
with autologous bone marrow
transplantation
NED at N14
years
my,
0 Para-aortic
LN
Chemotherapy: ifosfamide and
etoposide,
followed by high-dose
chemotherapy
(carboplatin, etoposide,
melphalan)
with autologous bone marrow
transplantation.
NED at N10
years.
side 20 Para-aortic
LN
Surgery: para-aortic LN
dissection and biopsy of the
omentum.
Radiotherapy: para-aortic LN
NED at 15
years
y; RSO: right salpingo-oophorectomy; LN: Lymph node; NED: no evidence of disease.
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SCCOHT, with 75 patients (50%) having stage I disease. Fourteen of the
forty two patients (33%) with stage IA disease for whom follow-up in-
formation was available remained without evidence of disease an aver-
age of 5.7 years following surgery (range 1–13 years). The remaining 28
patients (67%) with stage IA disease developed recurrent disease, with
the majority dying of their disease. Five of the 14 patients with stage
IA disease received adjuvant radiotherapy, and four (80%) are long-
term survivors, suggesting that radiotherapy may have a role in the ad-
juvant therapy of this tumor. A previous study by Dickersin et al. (1982)
described 11 patients with stage I/II SCOOHT. All patients were treated
with surgery; four patients received adjuvant chemotherapy, four pa-
tients received adjuvant radiotherapy, and three patients received no
adjuvant treatment. Two patients experienced durable responses with
radiotherapy alone after initial surgery. Another series by Harrison
et al. (2006) reported on 17 cases of SCCOHT. All patients underwent
surgery and adjuvant platinum-based chemotherapy. Sevenpatients re-
ceived adjuvant radiotherapy, and ﬁve (71%) are long-term survivors.
Three of the four patientswith stage I diseasewhodid not receive radio-
therapy developed recurrent disease. The results of these reports sug-
gest that radiotherapy may play an important role in the primary
treatment of SCCOHT.
Additional reports also provide evidence for radiotherapy in the
treatment of recurrent SCCOHT. Young et al. (1994) and Cannon et al.
(1975) described a patientwith stage IA diseasewhodeveloped a pelvic
recurrence 12 months following a right salpingo-oophorectomy with-
out adjuvant treatment. She underwent secondary tumor reductive sur-
gery, pelvic radiotherapy and chemotherapy and remained without
evidence of disease 10 years after completing therapy for recurrent dis-
ease. Furthermore, the series by Young et al. (1994) described two pa-
tients treated with chemotherapy and radiotherapy for recurrent
disease that were alive at 3.8 and 7 years after completing treatment.
Given the rarity of SCCOHT, the available literature consists of small
case series and single patient case reports. A review of the literaturewas
therefore performed to evaluate patients who had a sustained complete
response following treatment for recurrent SCCOHT, similar to the one
presented in this report. Including the patient described in our report,
10 patients were identiﬁedmeeting these criteria (Table 1). Themedian
age at diagnosis was 21 years (range 10–35 years). Six patients had
stage I disease (60%), three had stage II disease (30%) and one had
stage III disease (10%). Nine patients (90%) underwent initial unilateral
salpingo-oophorectomy. Eight patients (80%) initially underwent adju-
vant chemotherapy, one (10%) underwent radiotherapy alone, and one
(10%)did not receive any adjuvant treatment. All patients developed re-
current disease in the pelvis and/or abdomen. Surgery for recurrentdisease was performed in eight patients, with two patients receiving
no other adjuvant treatment for recurrence. Two patients had surgery
followed by radiotherapy, two had surgery followed by chemotherapy,
including one patient treated with high dose chemotherapy followed
by autologous bone marrow transplantation; and two had surgery
followed by radiotherapy and chemotherapy. Two patients did not un-
dergo surgery and received chemotherapy alone, including one patient
treated with high dose chemotherapy followed by autologous bone
marrow transplantation. All patients had complete response after recur-
rent disease and were alive and without evidence of disease at time of
publication.
Conclusion
We describe the case of a patient with SCCOHT with long-term sur-
vival despite recurrent disease. Rare cases have been reported in the lit-
erature suggesting that some patients with recurrent disease may
respond to salvage surgery, chemotherapy, radiotherapy or a combina-
tion of these modalities.
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